LGALS3 and pulmonary fibrosis: Gal-3 inhibition has been shown to reduce adenovirus-induced lung fibrosis, and an inhibitor is currently in Phase IIb clinical trials for IPF treatment (Mackinnonet al., 2012;Saitoet al., 2019).